All In Biotech

Free tool

FAERS Monitor: Cysview Kit

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022555 or its brand name (Cysview Kit, Hexaminolevulinate Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

44

Serious

9

20% of reports

Hospitalization

2

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective9
  • medication error4
  • pain4
  • anaphylactic shock3
  • burning sensation3
  • hypersensitivity3
  • micturition urgency3
  • accidental exposure to product2
  • cardiac arrest2
  • cardio-respiratory arrest2
  • hyperhidrosis2
  • hypotension2
  • no adverse event2
  • occupational exposure to product2
  • tachycardia2

Reports by year received

View as table
YearReports
20141
20155
20163
20173
20185
20197
20206
20211
20231
20247
20255

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,115 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
occupational exposure to product2148.838.4164
micturition urgencySignal3125.642.1257
anaphylactic shockSignal355.618.7111
medication errorSignal434.413.599
cardio-respiratory arrest222.95.923
burning sensationSignal320.56.938
cardiac arrest211.63.010
tachycardia210.82.89
accidental exposure to product29.32.48
hypersensitivitySignal37.72.612
hyperhidrosis27.41.96
no adverse event25.31.43
hypotension24.81.23
drug ineffectiveSignal93.31.813
pain43.11.24

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.